Evidence map›Paper›PMID 29602802›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Feng Wang, Xiaojun Xia, Chunying Yang, Jianliang Shen, Junhua Mai, Han-Cheon Kim, Dickson Kirui, Ya'an Kang, Jason B Fleming, Eugene J Koay and 3 more

Open access · greenAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Feng Wang *Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Xiaojun Xia *Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Chunying Yang *Department of Radiation Oncology, Houston Methodist Research Institute, Houston, Texas.
Jianliang ShenDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Junhua MaiDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Han-Cheon KimDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Dickson KiruiDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Ya'an KangDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jason B FlemingDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Eugene J KoayDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sankar MitraDepartment of Radiation Oncology, Houston Methodist Research Institute, Houston, Texas.
Mauro FerrariDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Haifa ShenDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas. hshen@houstonmethodist.org.
Houston Methodist · USThe University of Texas MD Anderson Cancer Center · US

Funding

TRANS-NETWORK PROJECTSU54CA143837 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2009 to 2014
$10.8M
Transport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHANG, JENNY C-N · 2016 to 2020
$9.3M
Tumor vasculature-targeted nanotherapeutics for DNA damage responseR01CA193880 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA193880NCI NIH HHS U54 CA143837NCI NIH HHS U54 CA210181
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationAnimalsAntineoplastic AgentsApoptosisAutophagyBiomarkers, TumorCell Line, TumorCell ProliferationCell SurvivalDisease Models, AnimalDNA DamageGene Knockdown TechniquesGenomic InstabilityHumansImmunohistochemistryMiceAntineoplastic AgentsBiomarkers, TumorReactive Oxygen SpeciesSmad4 ProteinSMAD4 protein, human

Identifiers

PMID29602802
PMCPMC6345154
OpenAlexW2794847062

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.